• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Congress of the International Society of Nutrigenetic/Nutrigenomics >Disappointing Recent Cholesterol-Lowering Drug Trials: Is It Not Time for a Full Reappraisal of the Cholesterol Theory?
【24h】

Disappointing Recent Cholesterol-Lowering Drug Trials: Is It Not Time for a Full Reappraisal of the Cholesterol Theory?

机译：令人失望的最近胆固醇降低的药物试验：它不是胆固醇理论的全部重新获得的时间吗？

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent cholesterol-lowering drug trials have been very disappointing for cholesterol experts and the cholesterol drug industry. Three events as important in terms of media coverage as of science and medicine are held each year around the issue of cholesterol: the annual meeting of the American College of Cardiology in March, the annual meeting of the European Society of Cardiology in August, and the American Heart Association meeting in November. Because thousands of cardiologists from all continentsare at the same place at the same time, each of these meetings is an opportunity to roll out cholesterol drug marketing campaigns. Today, marketing is primarily based on the publication of results of randomized trials. Thus every year, the three cardiology 'world meetings' are the best time to re-launch the cholesterol-lowering drug machine. However, the year 2008 has been a sad year because trial results obviously do not support the theory according to which cholesterol lowering results have significant benefits in the prevention of coronary heart disease (CHD), including the so-called 'the lower the better theory'.
机译：最近胆固醇的药物试验对胆固醇专家和胆固醇药业来说非常令人失望。在诸如科学和医学的媒体覆盖范围内的三个事件在胆固醇问题周围举行：3月份美国心脏病学院的年会，欧洲心脏病学年8月份的年会，以及11月美国心脏协会会议。因为来自所有在同一个地方的大洲的成千上万的心脏病学家同时，这些会议中的每一个都有机会推出胆固醇药物营销活动。如今，营销主要基于随机试验结果的出版。因此，每年，三个心脏病学“世界会议”是重新启动胆固醇降低药物机器的最佳时机。然而，2008年一年是悲伤的一年，因为试验结果显然不支持根据哪种理论，降低结果在预防冠心病（CHD）中具有显着益处，包括所谓的“更好的理论较低” '。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号